AGP 100
Alternative Names: AGP-100; DART-8569Latest Information Update: 11 Jan 2026
At a glance
- Originator Agiana Pharmaceuticals
- Class Heart failure therapies; Small molecules
- Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Polymorphic catecholergic ventricular tachycardia
Most Recent Events
- 02 Jan 2026 Phase-II clinical trials in Polymorphic catecholergic ventricular tachycardia in Norway (PO) (NCT07263139)
- 16 Oct 2025 Agiana Pharmaceuticals plans a phase-IIa trial for Polymorphic catecholergic ventricular tachycardia (In adults, In adolescents) in Norway (PO) (CTIS2025-521611-39-00)
- 16 Oct 2025 Preclinical trials in Polymorphic catecholergic ventricular tachycardia in USA (PO)